摘要 |
The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.
|
申请人 |
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION;THE UNIVERSITY OF MELBOURNE;THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH;CSL LIMITED;SHERRITT, MARTINA, ALISON;BURROWS, SCOTT, RENTON;KHANNA, RAJIV |
发明人 |
BURROWS, SCOTT, RENTON;KHANNA, RAJIV |